Key result
Viral infections account for ~30% of infectious complications and significant morbidity in lung transplant recipients.
Why the study?
Viral infections remain a major cause of morbidity and mortality in lung transplant recipients, and new therapeutic and preventive strategies are needed for non-CMV viruses and COVID-19.
Population
Lung transplant recipients
Design
Review
Authors
Loading...
Supports continued viral surveillance in lung transplant recipients; leaves open optimal prevention strategies in contemporary cohorts.
Appropriate management of viral complications, including CMV, respiratory viruses, and COVID-19, remains essential to improve survival and quality of life in lung transplant recipients.
Munting et al. (2021) conducted a review in Viral infections in lung transplant recipients. Viral infections account for up to 30% of all infectious complications in lung transplant recipients, remaining a significant cause of morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: